Abstract:Funding source: SERB SAS Award Identifier / Grant number: Honoraria Funding source: Protherics Medicines Development Ltd. Award Identifier / Grant number: Research Grant Sebastian Kühn (Labor Berlin – Charité Vivantes Services GmbH) is acknowledged for excellent technical support. The authors are grateful to all patients who participated in this study. We thank Dr. Katharina Friedrich, Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité – Universitätsmedizin Berlin, for her support in formatting the manuscript and critical input for result interpretation. FLK is MD candidate at Charité – Universitätsmedizin Berlin. This work is submitted in fulfillment of the requirement for the medical dissertation. Research ethics: This study was approved by the Ethics Committee of the Charité – Universitätsmedizin Berlin (ref. No. EA4/258/21) and was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards. Author contributions: FLK, SL, SS, AJ, UK, and KK contributed to the conception and design of the study, acquisition of data, data analysis and interpretation, and revised the article critically. PK, MP, IM and TK performed acquisition of data and data analysis. FLK, SS and AJ drafted the article, and revised the article critically for important intellectual content. The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Competing interests: Stefan Schwartz has received honoraria from SERB SAS and a research grant from Protherics Medicines Development Ltd for the present study. All other authors declare no competing financial interests. Research funding: Stefan Schwartz has received honoraria from SERB SAS and a research grant from Protherics Medicines Development Ltd for the present study. Data availability: The raw data can be obtained on request from the corresponding author. Trial registration: This study is registered at ClinicalTrials.gov: NCT05250869. 1. Widemann, BC, Adamson, PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694–703. https://doi.org/10.1634/theoncologist.11-6-694. Search in Google Scholar PubMed 2. Garneau, AP, Riopel, J, Isenring, P. Acute methotrexate-induced crystal nephropathy. N Engl J Med 2015;373:2691–3. https://doi.org/10.1056/nejmc1507547. Search in Google Scholar PubMed 3. Sherwood, RF, Melton, RG, Alwan, SM, Hughes, P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem 1985;148:447–53. https://doi.org/10.1111/j.1432-1033.1985.tb08860.x. Search in Google Scholar PubMed 4. Schwartz, S, Borner, K, Muller, K, Martus, P, Fischer, L, Korfel, A, et al.. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007;12:1299–308. https://doi.org/10.1634/theoncologist.12-11-1299. Search in Google Scholar PubMed 5. Widemann, BC, Balis, FM, Kim, A, Boron, M, Jayaprakash, N, Shalabi, A, et al.. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010;28:3979–86. https://doi.org/10.1200/jco.2009.25.4540. Search in Google Scholar 6. Widemann, BC, Sung, E, Anderson, L, Salzer, WL, Balis, FM, Monitjo, KS, et al.. Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 2000;294:894–901. Search in Google Scholar 7. Widemann, BC, Balis, FM, Murphy, RF, Sorensen, JM, Montello, MJ, O'Brien, M, et al.. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients -Abstract Truncated-

Periprosthetic seromas and a third space effect after high-dose methotrexate

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management.

Monitoring the plasma concentration of high-dosage of methotrexate during chemotheraphy for osteosarcoma and its clinical significance

Relationship of Serum Methotrexate Concentration in High-Dose Methotrexate Chemotherapy to Prognosis and Tolerability: A Prospective Cohort Study in Chinese Adults with Osteosarcoma

Serum concentration monitoring and significance of methotrexate in patients with osteosarcoma undergoing chemotherapy

High dose methotrexate in chemotherapy for osteosarcoma of the extremities: 63 cases report

Risk factors associated with liver damage induced by high-dose methotrexate treatment of osteosarcoma

Clinical Pharmacist’s Involvement in Treatment of Delayed Excretion of Large Doses of Methotrexate in Post-drug Period:Case Analysis

Complications of tumour overkill when associated with high dose methotrexate therapy

Measurements of Serum Drug Level for MTX and Analysis of Its Factors That Work on During the Chemotherapy of Osteosarcoma

Simplified preanalytical laboratory procedures for therapeutic drug monitoring (TDM) in patients treated with high-dose methotrexate (HD-MTX) and glucarpidase

Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Enhanced Antitumor Efficacy of Poly(d, L-lactide-co-glycolide)-based Methotrexate-Loaded Implants on Sarcoma 180 Tumor-Bearing Mice

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model

CASE SERIES ON METHOTREXATE INDUCED BONE MARROW SUPPRESSION

Atypical fractures of the lower extremities in two patients with rheumatoid arthritis: clinical presentations of presumed methotrexate osteopathy

Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma

Predictive Value of Cystatin C in Methotrexate Elimination in Patients with Osteosarcoma.

MTX Osteopathy Versus Osteoporosis Including Response to Treatment Data—A Retrospective Single Center Study Including 172 Patients

High-Dose Methotrexate (HD-MTX) Used As an Adjunct with Other Chemotherapeutics for the Treatment of Osteosarcoma